Electron and high-dose-rate brachytherapy boost in the conservative treatment of stage I-II breast cancer: First results of the randomized Budapest boost trial

Strahlentherapie und Onkologie

Volumn 178, Issue 11, 2002, Pages 615-623

  Polgár, Csaba ^a   Fodor, János ^a   Orosz, Zsolt ^a   Major, Tibor ^a   Takácsi Nagy, Zoltán ^a   Csaba Mangel, László ^a   Sulyok, Zoltán ^a   Somogyi, András ^a   Kásler, Miklós ^b   Németh, György ^a  

^a NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Boost irradiation; Brachytherapy; Breast cancer; Breast conserving therapy; Electron; Local recurrence

Indexed keywords

COBALT; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; IRIDIUM 192; METHOTREXATE; TAMOXIFEN;

ADULT; AGE; AGED; ARTICLE; BRACHYTHERAPY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER STAGING; CLINICAL TRIAL; CONSERVATIVE TREATMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ELECTRON THERAPY; ESTHETICS; FAT NECROSIS; FEMALE; FIBROSIS; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MITOSIS RATE; MULTIVARIATE ANALYSIS; PROGNOSIS; PROSPECTIVE STUDY; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SKIN TOXICITY; SURVIVAL RATE; SURVIVAL TIME; TELANGIECTASIA;

BRACHYTHERAPY; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; ELECTRONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HUNGARY; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; RADIOTHERAPY, ADJUVANT; RADIOTHERAPY, HIGH-ENERGY; RISK FACTORS;

EID: 0036854841     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00066-002-1053-1     Document Type: Article

References (64)

1. Anscher MS, Jones P, Prosnitz LR, et al. Local failure and margin status in early-stage breast carcinoma treated with conservation surgery and radiation therapy. Ann Surg 1993;218:22-8.
2. Arriagada R, Le MG, Rochard F, et al. Conservative treatment versus mastectomy in early breast cancer: Patterns of failure with 15 years of follow-up data. J Clin Oncol 1996;14:1558-64.
3. Bartelink H, Horiot JC, Poortmans P, et al. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med 2001;345:1378-87.
4. Bayerl A, Frank D, Lenz A, et al. Local tumor control and cosmetic outcome following breast-conserving surgery and radiation up to a total dose of 56 Gy without boost in breast cancer. Strahlenther Onkol 2001;177:25-32.
5. Blichert-Toft M, Rose C, Andersen, JA, et al. Danish randomized trial comparing breast conservation therapy with mastectomy: Six years of life-table analysis. J Natl Cancer Inst Monogr 1992;11:19-25.
6. Borger J, Kemperman H, Hart A, et al. Risk factors in breast-conservation therapy. J Clin Oncol 1994;12:653-60.
7. Clark RM, Whelan T, Levine M, et al. Randomized clinical trial of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer: An update. J Natl Cancer Inst 1996;88:1659-64.
8. Clarke DH, Vicini F, Jacobs H, et al. High dose rate brachytherapy for breast cancer. In: Nag S, ed. High Dose Rate Brachytherapy: A Textbook. Armonk/NY: Futura, 1994:321-9.
9. Cox DR. Regression models and life tables. J R Stat Soc 1972;34:187-220.
10. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organisation for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biolt Phys 1995;31:1341-6.
11. De la Rochefordière A, Abner A, Silver B, et al. Are cosmetic results following conservative surgery and radiation therapy for early breast cancer dependent on technique? Int J Radiat Oncol Biol Phys 1992;23:925-31.
12. De la Rochefordière A, Asselain B, Campana F, et al. Age as a prognostic factor in premenopausal breast carcinoma. Lancet 1993;341:1039-43.
13. Elkhuizen PHM, Van de Vijver MJ, Hermans J, et al. Local recurrence after breast-conserving therapy for invasive breast cancer: High incidence in young patients and association with poor survival. Int J Radiat Oncol Biol Phys 1998;40:859-67.
14. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology 1991;19:403-10.
15. Fisher B, Anderson S, Redmond CK, et al. Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 1995;333:1456-61.
16. Fisher B, Constantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen receptor-positive tumors. N Engl J Med 1989; 320:479-84.
17. Fisher B, Dignam J, Mamounas EP, et al. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: Eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyctophosphamide, methotrexate, and fluorouracil. J Clin Oncol 1996;14:1982-92.
18. Fisher B, Wickerham DL, Deutsch M, et al. Breast tumour recurrence following lumpectomy with and without breast irradiation: An overview of recent NSABP findings. Semin Surg Oncol 1992;8:153-60.
19. Fisher ER, Anderson S, Redmond C, et al. Ipsilateral breast tumour recurrence and survival following lumpectomy and irradiation: Pathological findings from NSABP protocol B-06. Semin Surg Oncol 1992;8:161-6.
20. Fodor J, Major T, Polgár C, et al. The impact of radiotherapy on the incidence and time of occurrence of local recurrence in early-stage breast cancer after breast conserving therapy. Neoplasma 2000;47:181-6.
21. Frazier RC, Kestin LL, Kini V, et al. Impact of boost technique on outcome in early-stage breast cancer patients treated with breast-conserving therapy. Am J Clin Oncol 2001;24:26-32.
22. Hammer J, Mazeron JJ, Van Limbergen E. Breast boost - Why, how, when...? Strahlenther Onkol 1999;175:478-83.
23. Hammer J, Seewald DH, Track C, et al. Breast cancer: Primary treatment with external-beam radiation therapy and high-dose-rate iridium implantation. Radiology 1994;193:573-77.
24. Hammer J, Track C, Seewald DH, et al. 192-Iridium HDR boostin in breast cancer treatment - Experience from 644 patients. Radiother Oncol 2000;55: Suppl 1:32.
25. Hellman S. Improving the therapeutic index in breast cancer treatment. Cancer Res 1980;40:4335-42.
26. Hennequin C, Durdux C, Espié M, et al. High-dose-rate brachytherapy for early breast cancer: An bulatory technique. Int J Radiat Oncol Biol Phys 1999;45:85-90.
27. Jacobs H. HDR afterloading experience in breast conservation therapy. Selectron Brachyther J 1992;6:14-7.
28. Jacobson JA, Danforth DN, Cowan KH, et al. Ten-year results of a comparison of conservation with mastectomy in the treatment of stage I and II breast cancer. N Engl J Med 1995;332:907-11.
29. Joiner MC. Linear-quadratic approach to fractionation. In: Steel GG, ed. Basic Clinical Radiobiology, London: Arnold, 1993:55-64.
30. Joslyn SA. Radiation therapy and patient age in the survival from earlystage breast cancer. Int J Radiat Oncol Biol Phys 1999;44:821-6.
31. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
32. Kurtz JM. Which patients don't need a tumor-bed boost after whole-breast radiotherapy? Strahlenther Onkol 2001;177:33-6.
33. Levitt SH, Aeppli DM, Nierengarten ME. The impact of radiation on early breast carcinoma survival: A bayesian analysis. Cancer 1996;78:1035-42.
34. Liljegren G, Holmberg L, Adami HO, et al. Sector resection with or without postoperative radiotherapy for stage I breast cancer: Five-year results of a randomized trial. J Natl Cancer Inst 1994;86:717-22.
35. Manning MA, Arthur DW, Schmidt-Ullrich RK, et al. Interstitial high-doserate brachytherapy boost: The feasibility and cosmetic outcome of a fractionated outpatient delivery scheme. Int J Radiat Oncol Biol Phys 2000; 48:1301-6.
36. Mansfield CM, Komarnicky LT, Schwartz GF, et al. Ten-year results in 1070 patients with stages I and II breast cancer treated by conservative surgery and radiation therapy. Cancer 1995;75:2328-36.
37. 192Ir implant after breast-preserving surgery in women with early breast cancer. Int J Radiat Oncol Biol Phys 2000;48:757-65.
38. Nag S, Kuske RR, Vicini FA, et al. Brachytherapy in the treatment of breast cancer. Oncology (Huntingt) 2001;15:195-202.
39. NIH Consensus Conference. Treatment of early-stage breast cancer. JAMA 1991;265:391-5.
40. Park C, Mitsumori M, Nixon A, et al. Outcome at 8 years after breast-conserving surgery and radiation therapy for invasive breast cancer: Influence of margin status and systemic therapy on local recurrence. J Clin Oncol 2000;18:1668-75.
41. Perez CA, Taylor ME, Halverson K, et al. Brachytherapy or electron beam boost in conservation therapy of carcinoma of the breast: A nonrandomized comparison. Int J Radiat Oncol Biol Phys 1996;34:995-1007.
42. Pezner RD, Lipsett JA, Desai K, et al. To boost or not to boost: Decreasing radiation therapy in conservative breast cancer treatment when "inked" tumor resection margins are pathologically free of cancer. Int J Radiat Oncol Biol Phys 1988;14:873-7.
43. Pierquin B, Dutreix A, Paine CH, et al. The Paris System in interstitial radiation therapy. Acta Radiol Oncol 1978;17:33-48.
44. Polgár C, Major T, Somogyi A, et al. CT-image based conformal brackytherapy of breast cancer: The significance of semi-3-D and 3-D treatment planning. Strahlenther Onkol 2000;176:118-24.
45. Polgár C, Sulyok Z, Fodor J, et al. Sole brachytherapy of the tumor bed after conservative surgery for T1 breast cancer: Five-year results of a phase I-II study and initial findings of a randomized phase III trial. J Surg Oncol 2002;80:121-8.
46. Recht A, Silver B, Schnitt SJ, et al. Breast relapse following primary radiation therapy for early breast cancer. Int J Radiat Oncol Biol Phys 1985; 11:1271-6.
47. Romestaing P, Lehingue Y, Carrie C, et al. Role of a 10-Gy boost in the conservative treatment of early breast cancer: Results of a randomized clinical trial in Lyon, France. J Clin Oncol 1997;15:963-8.
48. Sarin R, Dinsaw KA, Shrivastava SK, et al. Therapeutic factors influencing outcome and late complications in the conservative management of early breast cancer. Int J Radiat Oncol Biol Phys 1993;27:285-92.
49. Sauer R, Schauer A, Rauschecker HF, et al. Breast preservation versus mastectomy in early breast cancer - 1991 Update of the GBSG 1 - Protocol and prognostic factors. Strahlenther Onkol 1992;168:191-202.
50. Schmidt-Ullrich RK, Wazer DE, DiPetrillo T, et al. Breast conservation therapy for early stage breast carcinoma with outstanding 10-year locoregional control rates: A case for aggressive therapy to the tumor bearing quadrant. Int J Radiat Oncol Biol Phys 1993;27:545-52.
51. Schnitt SJ, Abner A, Gelman R, et al. The relationship between microscopic margins of resection and the risk of local recurrence in patients with breast cancer treated with breast-conserving surgery and radiation therapy. Cancer 1994;74:1746-51.
52. Schnitt SJ, Conolly JL, Harris JR, et al. Pathologic predictors of early local recurrence in stage I and II breast cancer treated by primary radiation therapy. Cancer 1984;53:1049-57.
53. Schuck A, Konemann S, Heinen K, et al. Microscopic residual disease is a risk factor in the primary treatment of breast cancer. Strahlenther Onkol 2002;178:307-13.
54. Smitt MC, Nowels KW, Zdeblick MJ, et al. The importance of the lumpectomy surgical margin status in long term results of breast conservation. Cancer 1995;76:259-67.
55. Touboul E, Belkacemi Y, Lefranc JP, et al. Early breast cancer: Influence of type of boost (electrons vs iridium-192 implant) on local control and cosmesis after conservative surgery and radiation therapy. Radiother Oncol 1995;34:105-13.
56. Van Dongen JA, Bartelink H, Fentiman IS, et al. Randomized clinical trial to assess the value of breast-conserving therapy in stage I and II breast cancer, EORTC 10801 Trial. J Natl Cancer Inst Monogr 1992;11:15-8.
57. Van Limbergen E, Van den Bogaert W, Van der Schueren E, et al. Tumor excision and radiotherapy as primary treatment of breast cancer. Analysis of patient and treatment parameters and local control. Radiother Oncol 1987;8:1-9.
58. Veronesi U, Banfi A, Salvadori B, et al. Breast conservation is the treatment choice in small breast cancer: Long-term results of a randomized trial. Eur J Cancer 1990;26:668-70.
59. Vicini FA, Horwitz EM, Lacerna MD, et al. Long-term outcome with interstitial brachytherapy in the management of patients with early-stage breast cancer treated with breast-conserving therapy. Int J Radiat Oncol Biol Phys 1997;37:845-52.
60. Vrieling C, Collette L, Fourquet A, et al. The influence of patient, tumor and treatment factors on the cosmetic results after breast-conserving therapy in the EORTC "boost vs. no boost" trial. Radiother Oncol 2000;55:219-32.
61. Wazer DE, Kramer B, Schmid C, et al. Factors determining outcome in patients treated with interstitial implantation as a radiation boost for breast conservation therapy. Int J Radiat Oncol Biol Phys 1997;39:381-93.
62. Wazer DE, Schmidt-Ullrich RK, Ruthazer R, et al. Factors determining outcome for breast-conserving irradiation with margin-directed dose escalation to the tumor bed. Int J Radiat Oncol Biol Phys 1998;40:851-8.
63. WHO. Histological Typing of Breast Tumours, 2nd Edn. Geneva: WHO, 1981.
64. Zutewski J, Liu ET. The 1998 St. Gallen's Consensus Conference: An assessment. J Natl Cancer Inst 1998;90:1587-9.